In this video, Charu Aggarwal, MD, MPH, the Leslye M. Heisler Professor for Lung Cancer Excellence at University of ...

New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relacorilant plus nab-paclitaxel showed a PFS benefit in patients with ...

Immune checkpoint inhibitors have shown efficacy in other HPV-related cancers, so a phase 2 trial tested avelumab treatment for locally advanced or metastatic penile cancer.

NovoCure Ltd. (($NVCR)) announced an update on their ongoing clinical study. The LUNAR-2 study by NovoCure Ltd. aims to evaluate the effectiveness ...

Genelux Corp. (($GNLX)) announced an update on their ongoing clinical study. Genelux Corp. is currently conducting a Phase 2 clinical study titled ...

Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

“The results of our analysis showed that overall, patients with SCLC who survived to receive 3L treatment are a select group ...

Real-world study confirmed that longer platinum-free interval was associated with better survival and prolonged 2L treatment duration in pts with endometrial cancer.

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...

Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in ...

These data support the use of pembrolizumab plus weekly paclitaxel, with or without bevacizumab, as a new standard of care for patients with platinum-resistant, recurrent ovarian cancer,” said ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...